BofA sees domestic growth, Semaglutide opportunity driving pharma in FY27
India’s pharmaceutical sector enters FY27 on a strong footing, backed by improving domestic demand, new product opportunities and healthy balance sheets, according to Neha Manpuria, Senior Analyst – Pharma, Healthcare at BofA Global Research. The March quarter reflected broad-based strength across the industry, with domestic formulations emerging as a key growth driver. Market growth in…
